Search 

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company, wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark. LEO Pharma is a leader in medical dermatology and developes, manufactures and markets pharmaceutical drugs for medical dermatology and thrombosis in more than 100 countries globally. We offer patients and physicians highly innovative and well-established products in Psoriasis, Atopic Dermatitis, Eczema, Acne, Rosacea.
LEO Pharma is continuously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets. LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.
To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.

We are keen for In-Licensing Assets for Global and Regional Rights for following: (1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases (2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities. (3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets (4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology
In addition we LEO Pharma has two early stage assets available for partnering.

LEO 142397 (LP0184) is an oral, super selective JAK 1 inhibitor for inflammatory diseases. Product is ready for phase 1 studies. Compound is available for global licensing or acquisition.

LEO 134310 (LP0155) is a SEGRA compound. It is topical, supersoft, non-steroidal Glucocorticoid Receptor (GR) agonist with improved systemic and local safety profile. LP0155 has demonstrated efficacy in clinical phase 1 studies. Compound is available for global licensing or acquisition.

MEDGENE is a T cell therapy biotech start-up (late pre-clinical stage) based in Maryland, USA.

- Focused on developing PD1+ peripheral blood-derived, tumor-reactive CD8+ T cell (PBTL) therapies as a platform for the treatment of solid tumors that are rare, orphan, and have critical (high) unmet need
- PBTL is a simpler, smarter version of TIL 
- PBTL is a process to select highly tumor-reactive T cells from a patient's peripheral blood based on the expression of two specific T cell surface markers: PD-1 and/or TIM-3 

- After selection, expanded to large quantities, it gets re-infused into the patient via the ACT regimen

- PBTL technology has been patented (issued) already in the US, China, the EU, Japan, Australia 
- MEDGENE has robust Clinical Development Pipelines (currently, 9 as monotherapy way)

- Looking for funding for entering Phase 1/2 in three pipelines in the US

- Looking for partnering for the Asian market (China, Japan, South Korea)

MediBase Group is an ITALIAN industrial company that has been operating since 1995 in the field of phytotherapy and medical dietetics; was one of the first companies to deal with Nutraceuticals through the preparation of products addressed exclusively to the health care professionals and distributed through the pharmacies, nursing homes and hospitals.
Titration and standardization are the most important quality criteria in the preparation of MediBase products.
The formulation of our preparations, the choice of active ingredients and their titration are based on accurate studies and analyzes of clinical works, published in the most prestigious international scientific journals, by our R&D.

NxR Biotechnologies is a boutique global consulting firm assisting life science companies and academic institutions conduct business development or investment initiatives. Particularly, NxR provides services for performing strategic, scientific, and commercial assessments; writing business plans; gathering competitive intelligence; and implementing entrepreneurship projects, partnership and in/out-licensing of conventional or regenerative medicine products, and commercialization deals. Areas of focus encompass the pharmaceutical industry and the white biotechnology industry. In the pharmaceutical industry, NxR focuses on cell-based and gene-based therapeutics, nucleic acid therapeutics, and biologics, in oncology, neurodegenerative diseases, inflammation, and rare diseases. In the white biotechnology industry, areas of specialization comprise sustainable chemicals including biomass conversion, biofuels, and polymers, as well as high value-added fermentation products including amino acids, proteins, and pharmaceuticals. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups.

Olympus was founded in 1919 and launched our first gastro-camera in the 1950s. Since then, Olympus developed into a MedTech leader, designing and delivering innovative solutions for medical and surgical procedures, especially in the field of endoscopy.

Santen Pharmaceutical Co., Ltd. (参天製薬株式会社), is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.

We are looking for investment and licensing opportunites in the ophthalmology field. 

Top medical device company in China focused on cardiovascular, surgical robotics and ten more fields.

MEDICAL AND MEDICINE INTL COOPAERATION AND INVESTMENT

Whale Bay & Co is a boutique financing firm focused solely on the life sciences industry. Based in Rotterdam (the Netherlands) and Basel (Switzerland) we serve SME's, investors and mid-size strategic companies in Biotech, Pharma, MedTech and Digital Health in the strategy and financial space: licensing, financing, M&A, valuation and outsources BD. We have a keen interest to expand our network and business into China. In the context of specific mandates we would like to connect with:

- pharma & medtech companies for outlicensing/JV collaborations with our clients
- investors looking for early and late stage pharma, biotech and medtech investment opportunities
- (FoF)investors interested in investment in funds